Concepedia

Age and fast initial response predict omalizumab retreatment in chronic urticaria

Michelle Meertens, Teddy Luijf, Esmee A.M. van Lindonk, Reineke Soegiharto, Salma Assil, Mehran Alizadeh Aghdam, Petra A. Kentie, André C. Knulst, Martijn B. A. van Doorn, Heike Röckmann

The Journal of Allergy and Clinical Immunology In Practice · 2023 · 12 citations · 2 references

DOIFull text

Open access

Concepts

Abstract

We found that omalizumab can be discontinued to reveal disease remission and avoid drug exposure in patients with chronic urticaria.Higher age and fast initial response predict the need for retreatment and can be used to counsel patients in clinical practice.

References

2

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Torsten Zuberbier, Amir Hamzah Abdul Latiff, Mohamed Abuzakouk et al. · Allergy · 2021 · 1.2K citations · Full text

, , +16

Effective omalizumab interval prolongation in the treatment of chronic urticaria

Mehran Alizadeh Aghdam, Rianne Henriëtte Pieterse, Petra A. Kentie et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 19 citations · Full text

, , +8